Inlyta

• 

New drug combination for advanced kidney cancer

By Sharon Kell|2019-04-25T08:21:25+00:0025 Apr 2019|Drug treatments|

Scientists have identified a promising new drug for renal cell [...]

Read More

Comments Off on New drug combination for advanced kidney cancer

• 

Targeted therapies with immunotherapies in kidney cancer

By Sharon Kell|2019-04-23T14:02:06+00:0023 Apr 2019|Drug treatments|

The following video is an interview with Professor Thomas Powles [...]

Read More

Comments Off on Targeted therapies with immunotherapies in kidney cancer

• 

Pembrolizumab plus axitinib granted FDA approval for advanced kidney cancer

By Sharon Kell|2019-04-23T13:41:19+00:0023 Apr 2019|Drug treatments|

The Food and Drug Administration (FDA) in the United States [...]

Read More

Comments Off on Pembrolizumab plus axitinib granted FDA approval for advanced kidney cancer

• 

Dalantercept plus axitinib combination for advanced kidney cancer

By Sharon Kell|2019-04-23T13:21:58+00:0023 Apr 2019|Drug treatments|

The results from a recent phase II study comparing a [...]

Read More

Comments Off on Dalantercept plus axitinib combination for advanced kidney cancer

• 

ASCO GU 2019: Avelumab plus axitinib combination superior to sunitinib

By Sharon Kell|2019-02-27T11:11:31+00:0027 Feb 2019|Drug treatments|

The results from the following study were presented at the [...]

Read More

Comments Off on ASCO GU 2019: Avelumab plus axitinib combination superior to sunitinib

• 

ASCO GU 2019: Pembrolizumab plus axitinib versus sunitinib for untreated metastatic RCC

By Sharon Kell|2019-02-26T11:04:31+00:0026 Feb 2019|Drug treatments|

The results from the following study were presented at the [...]

Read More

Comments Off on ASCO GU 2019: Pembrolizumab plus axitinib versus sunitinib for untreated metastatic RCC

• 

ASCO GU 2019: Gemcitabine plus axitinib in patients with sarcomatoid renal cell carcinoma (RCC)

By Sharon Kell|2019-02-26T10:07:18+00:0026 Feb 2019|Subtypes of RCC|

Results from this trial for sarcomatoid renal cell carcinoma (RCC) [...]

Read More

Comments Off on ASCO GU 2019: Gemcitabine plus axitinib in patients with sarcomatoid renal cell carcinoma (RCC)

• 

Second-line treatment with axitinib in favourable risk patients

By Sharon Kell|2019-02-04T10:34:55+00:004 Feb 2019|Drug treatments|

Results from a phase 2 study to assess the activity [...]

Read More

Comments Off on Second-line treatment with axitinib in favourable risk patients

• 

Comparison of axitinib and sunitinib as first-line treatment for metastatic kidney cancer

By Sharon Kell|2018-11-30T10:06:06+00:0030 Nov 2018|Drug treatments|

This multicentre analysis of axitinib versus sunitinib used as first-line [...]

Read More

Comments Off on Comparison of axitinib and sunitinib as first-line treatment for metastatic kidney cancer

• 

Results from JAVELIN Renal 101 clinical trial – avelumab plus axitinib combination for advanced kidney cancer

By Sharon Kell|2018-11-28T14:47:57+00:0028 Nov 2018|Drug treatments|

The following article from Practice Update discusses the JAVELIN Renal [...]

Read More

Comments Off on Results from JAVELIN Renal 101 clinical trial – avelumab plus axitinib combination for advanced kidney cancer